Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
Public ClinicalTrials.gov record NCT04739072. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Minimal Residual Disease Assessment in Colorectal Cancer (MiRDA-C)
Study identification
- NCT ID
- NCT04739072
- Recruitment status
- Recruiting
- Study type
- Observational
- Phase
- Not listed
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Enrollment
- 1,000 participants
Conditions and interventions
Conditions
- Colorectal Adenocarcinoma
- Stage I Colorectal Cancer AJCC v8
- Stage II Colorectal Cancer AJCC v8
- Stage IIA Colorectal Cancer AJCC v8
- Stage IIB Colorectal Cancer AJCC v8
- Stage IIC Colorectal Cancer AJCC v8
- Stage III Colorectal Cancer AJCC v8
- Stage IIIA Colorectal Cancer AJCC v8
- Stage IIIB Colorectal Cancer AJCC v8
- Stage IIIC Colorectal Cancer AJCC v8
- Stage IV Colorectal Cancer AJCC v6
- Stage IVA Colorectal Cancer AJCC v8
- Stage IVB Colorectal Cancer AJCC v8
- Stage IVC Colorectal Cancer AJCC v8
Interventions
- Biospecimen Collection Procedure
- Electronic Health Record Review Other
Procedure · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 21, 2019
- Primary completion
- Dec 30, 2025
- Completion
- Dec 30, 2025
- Last update posted
- Nov 12, 2025
2019 – 2025
United States locations
- U.S. sites
- 10
- U.S. states
- 6
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner - MD Anderson Cancer Center | Gilbert | Arizona | 85234 | Terminated |
| Baptist- MD Anderson Cancer Center | Jacksonville | Florida | 32207 | Terminated |
| The Queen's Medical Center | Honolulu | Hawaii | 96813 | Terminated |
| St. Luke's Cancer Institute | Boise | Idaho | 83712 | Terminated |
| Cooper Hospital UNIV MED CTR. | Camden | New Jersey | 08103 | Terminated |
| UT Southwestern/Simmons Cancer Center-Dallas | Dallas | Texas | 75390 | Terminated |
| Houston Methodist Cancer Center | Houston | Texas | 77030 | Terminated |
| M D Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| UT Health San Antonio MD Anderson Cancer Center | San Antonio | Texas | 78229 | Terminated |
| Baylor Scott & White Research Institute | Temple | Texas | 76508 | Terminated |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04739072, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 12, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04739072 live on ClinicalTrials.gov.